Selection process for trials.

<p>Selection process for trials.</p

Peto Odds ratio of vandetanib-associated all grade (A) and high-grade (B) prolonged QTc interval versus control from the randomized controlled trials of patients with non-thyroid cancer.

<p>Peto Odds ratio of vandetanib-associated all grade (A) and high-grade (B) prolonged QTc interval versus control from the randomized controlled trials of patients with non-thyroid cancer.</p

Peto Odds ratio of vandetanib-associated all grade (A) and high-grade (B) prolonged QTc interval versus control from the randomized controlled trials of patients with thyroid cancer.

<p>Peto Odds ratio of vandetanib-associated all grade (A) and high-grade (B) prolonged QTc interval versus control from the randomized controlled trials of patients with thyroid cancer.</p

Characteristics of clinical trials and patients included in the meta-analysis.

<p>NSCLC:non-small-cell lung cancer; SCLC:small-cell lung cancer; PC:paclitaxel and carboplatin; MTC:medullary thyroid cancer; DTC:differentiated thyroid cancer.</p

Forest plot for meta-analysis of incidence of all grade (A) and high-grade (B) prolonged QTc interval in patients with non-thyroid cancer who were assigned vandetanib.

<p>Forest plot for meta-analysis of incidence of all grade (A) and high-grade (B) prolonged QTc interval in patients with non-thyroid cancer who were assigned vandetanib.</p